All In Biotech

Drug Trial Radar · NCT05653349

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 226 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

226

Actual

Start

Feb 3, 2023

Primary completion

Oct 29, 2026

Study completion Aug 11, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in increasing the rate of stable response off treatment at 12 months (SROT-12) in adult participants with primary ITP.

Conditions

  • Primary Immune Thrombocytopenia (ITP)

Interventions

  • IanalumabBiological

    Intravenous infusion, prepared from concentrate solution

  • PlaceboDrug

    Intravenous infusion, prepared from matching placebo

  • CorticosteroidsDrug

    Oral or parental (if clinically justified)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Stable Response off treatment at 12 months (SROT-12)Time frame: 12 months after last patient completed treatment

Locations

99 sites in 25 countries. Site status is shown where the registry gives one.

  • Yuma Regional Medical Center

    Yuma, Arizona

  • Community Cancer Institute

    Clovis, California

  • Compassionate Care Res Group Inc

    Fountain Valley, California

  • University of Colorado Anschutz

    Aurora, Colorado

  • DH Cancer Research Center LLC

    Margate, Florida

  • Uni of Chi Medi Ctr Hema and Onco

    Chicago, Illinois

  • Parkview Research Center

    Fort Wayne, Indiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Med Center

    Boston, Massachusetts

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Hematology Oncology Association of Rockland

    Nyack, New York

  • Rhode Island Hospital

    Providence, Rhode Island

  • Mays Cancer Ctr Uthsa Mdacc

    San Antonio, Texas

  • Community Cancer Trials of Utah

    Ogden, Utah

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    San Miguel Tucuman, Tucumán Province, Argentina

  • Novartis Investigative Site

    Garran, Australian Capital Territory, Australia

  • Novartis Investigative Site

    Wooloongabba, Queensland, Australia

  • Novartis Investigative Site

    Clayton, Victoria, Australia

  • Novartis Investigative Site

    Salzburg, Austria

  • Novartis Investigative Site

    Innsbruck, Tyrol, Austria

  • Novartis Investigative Site

    Brasschaat, Belgium

  • Novartis Investigative Site

    Bruges, Belgium

  • Novartis Investigative Site

    Roeselare, West Vlaanderen, Belgium

  • Novartis Investigative Site

    Plovdiv, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Bengbu, China

  • Novartis Investigative Site

    Dalian, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Beijing, Beijing Municipality, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Shenzhen, Guangdong, China

  • Novartis Investigative Site

    Shijiazhuang, Hebei, China

  • Novartis Investigative Site

    Luoyang, Henan, China

  • Novartis Investigative Site

    Zhengzhou, Henan, China

  • Novartis Investigative Site

    Changzhou, Jiangsu, China

  • Novartis Investigative Site

    Nanchang, Jiangxi, China

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.